Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients
about
T-cell abnormalities in common variable immunodeficiency: the hidden defectInternational Consensus Document (ICON): Common Variable Immunodeficiency DisordersMechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary ImmunodeficienciesAutoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management.Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with RituximabAutoimmune cytopenias in common variable immunodeficiency.Contemporary treatment of immune thrombocytopenia.Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia.Thrombocytopenia in common variable immunodeficiency patients - clinical course, management, and effect of immunoglobulinsCommon variable immunodeficiency, immune thrombocytopenia, rituximab and splenectomy: important considerations.The many faces of common variable immunodeficiency.Comparisons of CVID and IgGSD: referring physicians, autoimmune conditions, pneumovax reactivity, immunoglobulin levels, blood lymphocyte subsets, and HLA-A and -B typing in 432 adult index patients.Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphomaExpansion of inflammatory innate lymphoid cells in patients with common variable immune deficiencyNijmegen breakage syndrome and chronic polyarthritis.Immunotherapy treatments of warm autoimmune hemolytic anemia.Autoimmune and Lymphoproliferative Complications of Common Variable Immunodeficiency.Management of granulomatous lymphocytic interstitial lung disease in a patient with common variable immune deficiency.Approach to the Management of Autoimmunity in Primary Immunodeficiency.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.Dysregulation of Innate Lymphoid Cells in Common Variable Immunodeficiency.Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort[Common variable immunodeficiency: a clinical challenge].Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.Splenectomy for Immune Thrombocytopenia: Down but not out.Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia.An Exponential Regression Model Reveals the Continuous Development of B Cell Subpopulations Used as Reference Values in Children.Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia
P2860
Q26751451-E9537B52-4FDE-4AD1-8050-92E3C3642D78Q26777304-39A68454-BFAF-4D6A-9D8C-66334BB93157Q28066193-DF075134-4079-40DC-BEAA-9EC39B555654Q30245322-7B9A7182-F1E8-4994-8FD6-BE7264DC7A8DQ31150752-38B042CE-B90C-4E45-9DAC-0CED43E43457Q33402558-9B589FAD-938C-4025-98D3-20CF2761FB91Q33410653-96275EF6-2A7B-45B7-B130-77D27BAAC72FQ33413528-3C62DB05-5746-482E-8B04-B7C85D628738Q33424258-3042B1C6-B0C5-4F74-BF22-023C6879A845Q33432871-F9687608-F747-462C-B70C-18D8F2780FD8Q33790739-81A38BA2-61CF-41E7-B514-B83B20FE64ABQ34268591-BBA1B356-A151-48A2-A336-0A0377BE25B8Q36671605-49846190-1161-409E-9CDD-8AD7E7B79C03Q36900160-77443D0F-95EE-4FA5-BDF1-6AA6AE322D90Q37362224-D05848B6-097D-4CC8-9136-5C59CA84CAD6Q38150845-9F972729-5D3D-4498-972D-315F3E8FF8DFQ38726509-EC477525-D882-415E-BAA0-424DB4557988Q38874082-A6D31D57-B3B3-4E78-8374-C588A55EA3BFQ39012945-DA606AE4-A777-4964-A973-684EBB5AA975Q39016299-54D43087-3440-4774-BFFD-F6BE5970ED54Q39453651-DC32E4BD-8BB2-4158-AD64-F131F7ECD69DQ40076704-D65F6272-54C5-481A-89FC-313A5A8FA3FAQ41990559-B69E132A-ECAB-44F8-AFC6-90EBB3FB7A13Q41990601-AF0A4F95-E7B9-4D6E-AD8B-B144E069D581Q45781154-6372FD4C-325A-4F8D-8DC3-BCFB9CD1518FQ47151016-C16B6210-473C-47F0-839D-994AC193AC1AQ47754303-4399D73B-FAF3-4F1B-BD89-49C627105607Q48335821-2BA7EF3D-6398-4963-A6F6-0C24F843CF06Q54940356-9D3C39B6-0667-45D9-92FB-E9C96BF6547CQ58376502-D4BB2B33-2C19-4578-A9A2-27F5F00DD95C
P2860
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@ast
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@en
type
label
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@ast
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@en
prefLabel
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@ast
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@en
P2093
P2860
P50
P1476
Efficacy and safety of rituxim ...... lticentre study on 33 patients
@en
P2093
Agnès Dechartres
Alain LeQuellec
Alice Berezne
Amar Smail
Christophe Auzary
Claire Larroche
Delphine Gobert
Jean-François Viallard
Lionel Galicier
Marc Michel
P2860
P304
P356
10.1111/J.1365-2141.2011.08880.X
P407
P577
2011-10-08T00:00:00Z